skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Percutaneous Thermal Ablation of Breast Cancer Metastases in Oligometastatic Patients

Abstract

ObjectiveTo evaluate prognostic factors associated with local control and disease-free-survival (DFS) of oligometastatic breast cancer patients treated by percutaneous thermal ablation (PTA).Materials and MethodsSeventy-nine consecutive patients (54.5 ± 11.2 years old) with 114 breast cancer metastases (28.9 ± 16.1 mm in diameter), involving the lungs, the liver, and/or the bone, were treated using PTA with a curative intent. The goal was to achieve a complete remission in association with systemic chemotherapy and hormonal therapy. We retrospectively evaluated the prognostic factors associated with 1- and 2-year local control and the 1- and 2-year DFS rates.ResultsThe 1- and 2-year local control rates were 83.0 and 76.1 %, respectively. Tumor burden was associated with a poorer outcome for local control after PTA (HR 1.027 by additional millimeter, p = 0.026; >4 cm HR 3.90). The 1- and 2-year DFS rates were 54.2 and 30.4 %, respectively. In multivariate analysis, triple-negative histological subtype and increased size of treated metastases were associated with a poorer DFS (HR 2.22; 95 % CI [1.13–4.36]; p = 0.02 and HR 2.43; 95 % CI [1.22–4.82]; p = 0.011, respectively).ConclusionPTA is effective for local control of breast cancer oligometastases. Tumor burden >4 cm and triple-negative histological subtype are associated with a poorer outcome.

Authors:
 [1];  [2]; ; ;  [1];  [3]; ; ;  [1]
  1. Institut Gustave Roussy, Interventional Radiology Department (France)
  2. Institut Gustave Roussy, Biostatistics and Epidemiology Unit (France)
  3. Centre Clinique de la Porte de Saint-Cloud, Radiotherapy (France)
Publication Date:
OSTI Identifier:
22642503
Resource Type:
Journal Article
Resource Relation:
Journal Name: Cardiovascular and Interventional Radiology; Journal Volume: 39; Journal Issue: 6; Other Information: Copyright (c) 2016 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); http://www.springer-ny.com; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ABLATION; CHEMOTHERAPY; CONTROL; HORMONES; LIVER; LUNGS; MAMMARY GLANDS; METASTASES; MULTIVARIATE ANALYSIS; NEOPLASMS; PATIENTS; PHOSPHORUS 36; SKELETON

Citation Formats

Barral, M., E-mail: matthias-barral@yahoo.fr, Auperin, A., E-mail: anne.auperin@gustaveroussy.fr, Hakime, A., E-mail: thakime@yahoo.com, Cartier, V., E-mail: victoirecartier@hotmail.com, Tacher, V., E-mail: vaniatacher@gmail.com, Otmezguine, Yves, E-mail: yotmezguine@ccps.com, Tselikas, L., E-mail: lambros.tselikas@gmail.com, Baere, T. de, E-mail: thierry.debaere@gustaveroussy.fr, and Deschamps, F., E-mail: frederic.deschamps@gustaveroussy.fr. Percutaneous Thermal Ablation of Breast Cancer Metastases in Oligometastatic Patients. United States: N. p., 2016. Web. doi:10.1007/S00270-016-1301-X.
Barral, M., E-mail: matthias-barral@yahoo.fr, Auperin, A., E-mail: anne.auperin@gustaveroussy.fr, Hakime, A., E-mail: thakime@yahoo.com, Cartier, V., E-mail: victoirecartier@hotmail.com, Tacher, V., E-mail: vaniatacher@gmail.com, Otmezguine, Yves, E-mail: yotmezguine@ccps.com, Tselikas, L., E-mail: lambros.tselikas@gmail.com, Baere, T. de, E-mail: thierry.debaere@gustaveroussy.fr, & Deschamps, F., E-mail: frederic.deschamps@gustaveroussy.fr. Percutaneous Thermal Ablation of Breast Cancer Metastases in Oligometastatic Patients. United States. doi:10.1007/S00270-016-1301-X.
Barral, M., E-mail: matthias-barral@yahoo.fr, Auperin, A., E-mail: anne.auperin@gustaveroussy.fr, Hakime, A., E-mail: thakime@yahoo.com, Cartier, V., E-mail: victoirecartier@hotmail.com, Tacher, V., E-mail: vaniatacher@gmail.com, Otmezguine, Yves, E-mail: yotmezguine@ccps.com, Tselikas, L., E-mail: lambros.tselikas@gmail.com, Baere, T. de, E-mail: thierry.debaere@gustaveroussy.fr, and Deschamps, F., E-mail: frederic.deschamps@gustaveroussy.fr. Wed . "Percutaneous Thermal Ablation of Breast Cancer Metastases in Oligometastatic Patients". United States. doi:10.1007/S00270-016-1301-X.
@article{osti_22642503,
title = {Percutaneous Thermal Ablation of Breast Cancer Metastases in Oligometastatic Patients},
author = {Barral, M., E-mail: matthias-barral@yahoo.fr and Auperin, A., E-mail: anne.auperin@gustaveroussy.fr and Hakime, A., E-mail: thakime@yahoo.com and Cartier, V., E-mail: victoirecartier@hotmail.com and Tacher, V., E-mail: vaniatacher@gmail.com and Otmezguine, Yves, E-mail: yotmezguine@ccps.com and Tselikas, L., E-mail: lambros.tselikas@gmail.com and Baere, T. de, E-mail: thierry.debaere@gustaveroussy.fr and Deschamps, F., E-mail: frederic.deschamps@gustaveroussy.fr},
abstractNote = {ObjectiveTo evaluate prognostic factors associated with local control and disease-free-survival (DFS) of oligometastatic breast cancer patients treated by percutaneous thermal ablation (PTA).Materials and MethodsSeventy-nine consecutive patients (54.5 ± 11.2 years old) with 114 breast cancer metastases (28.9 ± 16.1 mm in diameter), involving the lungs, the liver, and/or the bone, were treated using PTA with a curative intent. The goal was to achieve a complete remission in association with systemic chemotherapy and hormonal therapy. We retrospectively evaluated the prognostic factors associated with 1- and 2-year local control and the 1- and 2-year DFS rates.ResultsThe 1- and 2-year local control rates were 83.0 and 76.1 %, respectively. Tumor burden was associated with a poorer outcome for local control after PTA (HR 1.027 by additional millimeter, p = 0.026; >4 cm HR 3.90). The 1- and 2-year DFS rates were 54.2 and 30.4 %, respectively. In multivariate analysis, triple-negative histological subtype and increased size of treated metastases were associated with a poorer DFS (HR 2.22; 95 % CI [1.13–4.36]; p = 0.02 and HR 2.43; 95 % CI [1.22–4.82]; p = 0.011, respectively).ConclusionPTA is effective for local control of breast cancer oligometastases. Tumor burden >4 cm and triple-negative histological subtype are associated with a poorer outcome.},
doi = {10.1007/S00270-016-1301-X},
journal = {Cardiovascular and Interventional Radiology},
number = 6,
volume = 39,
place = {United States},
year = {Wed Jun 15 00:00:00 EDT 2016},
month = {Wed Jun 15 00:00:00 EDT 2016}
}